CKb;TSC;DCCK;DC-CK;Eotaxin;AMAC-1;CCL26;CKb7;DC-CK1;Eotaxin-3;IMAC;MIP-4;MIP-4a;SCYA26;TSC-1;AMAC1;MIP4;PARC;SCYA18;CCL18;AMAC-1;CKb7;DCCK1;DC-CK1;MIP-4;Alternative macrophage activation associated CC chemokine 1;Alternative macrophage activation-associated CC chemokine 1;CC chemokine PARC;C-C Motif Chemokine 18;CCL18(4-69);Dendritic cell chemokine 1;Macrophage inflammatory protein 4;Pulmonary and activation regulated chemokine;Pulmonary and activation-regulated chemokine;Small inducible cytokine A18;Small-inducible cytokine A18

E.coli

Ala21-Ala89

P55774

Human

27.4 kDa

30 kDa

N-Trx

Not validated for activity

> 90% as determined by reducing SDS-PAGE.

< 10 EU/mg of the protein as determined by the LAL method

Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

This product is provided as lyophilized powder which is shipped with ice packs.

Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol.

It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

CCL18/PARC is a chemotactic cytokine involved in the pathogenesis and progression of various disorders, including cancer. Proof showed high levels of CCL18/PARC in the serum of epithelial ovarian carcinoma patients sμggesting its potential as a circulating biomarker. CCL18/PARC chemokine has an important role in chemokine-mediated tumor metastasis, and may serve as a potential predictor for poor survival outcomes for ovarian cancer. (CCL18/PARC) is predominantly secreted by M2-tumor associated macrophages (TAMs) and promotes malignant behaviors of various human cancer types. CCL18/PARC has a correlation with cardiac function in patients with AAMI and it might be considered as an indicator of poor LVEF in patients with AAMI. Circulating and WAT-secreted CCL18/PARC correlates with insulin resistance and metabolic risk score. Because CCL18/PARC is macrophage-specific and associates with adipose immune gene expression, it may constitute a marker of WAT inflammation. Macrophages are thoμght to be the main source of CCL18/PARC, and the effect of pirfenidone, an anti-fibrotic agent for idiopathic pulmonary fibrosis, on the expression of CCL18/PARC in macrophages warrants investigation.